You are here:

Archived: Omalizumab 150mg powder and solvent for injection (Xolair)


Following a full submission.

Omalizumab (Xolair®) is not recommended for use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma.

The economic case for omalizumab has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Omalizumab 150mg powder and solvent for injection (Xolair)
SMC Drug ID: 259/06
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Asthma
BNF Category:
Submission Type: Full submission
Status: Superseded
Date Advice Published: 12 June 2006

Current Advice

Resubmission 8 October 2007

Archived Advice

Resubmission 15 January 2007